Dr. Kendra Lynn Sweet, MD
- Medicare services, 2024
- 44
- Medicare patients, 2024
- 28
- Part D claims, 2024
- 89
- Publications
- 93
- Clinical trials
- 9
- Practice address
- 12902 Magnolia Dr, Tampa, FL 33612
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Sweet's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Kendra Lynn Sweet is a hematologist and oncologist in Tampa, Florida
Dr. Sweet practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.
Dr. Sweet's NPI, 1609074574, was assigned on July 3, 2007. Dr. Sweet graduated from VCU School of Medicine in 2007. Dr. Sweet holds Florida license ME106128.
- NPI
- 1609074574NPI Registry (opens in a new tab)
- Medicare PAC ID
- 8426238973
- NPI enumeration date
- July 3, 2007
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 45
- Medical school graduation
- 2007
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Kendra Lynn Sweet practices at Moffitt Cancer Hospital in Tampa, Florida
Dr. Sweet's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.
- Moffitt Cancer Hospital12902 Magnolia Dr, Tampa, FL 33612
Source: Dmand AI Affiliation Data
Dr. Kendra Lynn Sweet is affiliated with 2 sites of care and 1 medical group
Dr. Sweet's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Sweet to 1 more group practice or clinic, named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Kendra Lynn Sweet's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sweet practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Moffitt Cancer Hospital | Available with a free account |
| +1 more affiliated site | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Moffitt Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Kendra Lynn Sweet is one of 693 hematologists and oncologists in Florida
Hematology and oncology is Dr. Sweet's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sweet is board certified in hematology by the American Board of Internal Medicine. Dr. Sweet is licensed in Florida.
Specialties and state licenses
- Hematology and oncology, FloridaPrimary
Clinical focus
Dmand AI lists chronic anemia, chronic leukemia, lung cancer, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Sweet treats.
Hematologists and oncologists near Dr. Sweet
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Kendra Lynn Sweet billed Medicare for 44 services in 2024
CMS data shows 44 Medicare services from Dr. Sweet across 1 procedure code in 2024, all of them office visits, for 28 Medicare patients. Medicare paid $2,803 for them. Every service was in a facility, such as a hospital, rather than an office.
Dr. Sweet's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 1372024: 4468%
Dr. Sweet compared with the Florida median for hematologists and oncologists, 2024
- Dr. Sweet
- Florida median
- Medicare services
- 44vs 69794% below
- Medicare patients
- 28vs 21887% below
- Part D claims
- 61vs 34182% below
Medians across 638 hematologists and oncologists in Florida with Dmand AI profiles that report each measure.
Dr. Sweet's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Sweet?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Sweet and other hematologists and oncologists in Florida.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Kendra Lynn Sweet treated 28 Medicare patients in 2024, average age 70
CMS counts 28 Medicare patients who saw Dr. Sweet in 2024. The largest group is 75 to 84, with 12 patients. 75% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Sweet's median patient age at 69, with 44% women.
Dr. Sweet's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Sweet's Medicare patients by sex, 2024
- Women1346%
- Men1554%
Chronic conditions among Dr. Sweet's Medicare patients, 2024
- High cholesterol75%
- High blood pressure71%
- Arthritis57%
- Chronic kidney disease50%
- Anxiety39%
Share of Medicare patients with each condition. A patient can have several.
Dr. Sweet's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 69
Patient panel by sex, all payers
- Women44%
- Men55%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Kendra Lynn Sweet wrote 89 Medicare Part D claims in 2024
In 2024, Dr. Sweet wrote 89 Medicare Part D claims for 17 patients. 36% of them were for generic drugs. CMS names the drug for 61 of them, across 4 drugs with 11 or more claims each, at $442,395 in total drug cost. In 2023, CMS named 114 claims across 6 drugs.
Dr. Sweet's Part D claims by kind of drug, 2024
- Generic32 claims36%
- Brand-name57 claims64%
Dr. Sweet's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 1142024: 6146%
Drugs named by CMS: 4 in 2024, 6 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Kendra Lynn Sweet scored 88 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Sweet for performance year 2024, reported as part of a group. Dr. Sweet accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Dr. Sweet's MIPS scores, performance year 2024
- 88of 100Final score
- 74of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 71of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Kendra Lynn Sweet has 93 publications on record
Dmand AI links 93 papers to Dr. Sweet, published from 2012 to 2025. 2024 was the busiest year, with 12. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Dr. Sweet has published most often in Clin Lymphoma Myeloma Leuk. Dr. Sweet's most frequent co-authors are Jeffrey E. Lancet, MD, Rami Salah-Eddin Komrokji, MD and David A. Sallman, MD.
Dr. Sweet's papers by year, 2016 to 2025
Topics Dr. Sweet writes about most
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Protein Kinase Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Hematopoietic Stem Cell Transplantation
- Remission Induction
- Pyrimidines
Dr. Sweet's most frequent co-authors
- Jeffrey E. Lancet, MD52 shared papers
- Rami Salah-Eddin Komrokji, MD49 shared papers
- David A. Sallman, MD44 shared papers
Recent publications by Dr. Sweet
See who Dr. Sweet researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Sweet works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Kendra Lynn Sweet has worked on 9 clinical trials
Dmand AI links Dr. Sweet to 9 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic-Phase and Myelodysplastic Syndromes. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4.
Clinical trials with Dr. Sweet by phase
- 1Phase 1: 1 trial
- 2Phase 1/2: 2 trials
- 3Phase 2: 3 trials
- 2Phase 3: 2 trials
- NonePhase 4: no trials
Conditions in Dr. Sweet's trials
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Myelodysplastic Syndromes
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
Investigators on the most trials with Dr. Sweet
- Rami Salah-Eddin Komrokji, MD4 shared trials
- Jeffrey E. Lancet, MD4 shared trials
- Eric Padron, MD4 shared trials
Recent clinical trials with Dr. Sweet
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (opens in a new tab)
Quality of Life Model for Older Patients With AML (opens in a new tab)
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors (opens in a new tab)
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS (opens in a new tab)
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Kendra Lynn Sweet received $231,905 in industry payments from 2016 to 2025
CMS Open Payments shows 200 general payments to Dr. Sweet from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Novartis Pharmaceuticals Corporation paid the most, $62,406. It also lists 6 research payments totaling $18,518 from 2017 to 2024.
General payments to Dr. Sweet by program year, 2016 to 2025
General payments to Dr. Sweet by kind, 2016 to 2025
- Consulting fees$140,27662%
- Speaker and faculty fees$33,26715%
- Education$24,02811%
- Travel and lodging$16,1637%
- Other$12,0465%
Companies that paid Dr. Sweet the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Kendra Lynn Sweet graduated from VCU School of Medicine
Dr. Sweet graduated from VCU School of Medicine in 2007.
- Medical school
- Board certified in hematology
- Board certified in internal medicine
- Board certified in medical oncology
Source: Dmand AI Professional Profile Data
Dr. Kendra Lynn Sweet accepts plans from 9 insurance carriers
Dr. Sweet is in network with 9 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.
- Excellus BlueCross BlueShield
- United Healthcare
- Blue Cross Blue Shield of Michigan
- Humana
- Molina
- Aetna
- Alliant Health Plans
- Blue Cross and Blue Shield of Kansas City
- +1 more carriersWith a free account
Plan types Dr. Sweet accepts, by number of carriers
- HMO6
- Medicare5
- POS4
- PPO4
- EPO2
Source: Dmand AI Insurance Network Data
Sources for Dr. Kendra Lynn Sweet's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Kendra Lynn Sweet
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Kendra Lynn Sweet's NPI number?
Dr. Kendra Lynn Sweet's NPI number is 1609074574. It was assigned on July 3, 2007, and it is active in the NPI Registry.
What kind of doctor is Dr. Kendra Lynn Sweet?
Dr. Kendra Lynn Sweet is a hematologist and oncologist in Tampa, Florida. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Kendra Lynn Sweet practice?
Dr. Sweet practices at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Sweet's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dmand AI also links Dr. Sweet to 1 group practice or clinic.
What is Dr. Kendra Lynn Sweet's medical license number?
Dr. Sweet holds Florida license ME106128.
Which hospitals is Dr. Kendra Lynn Sweet affiliated with?
Dr. Sweet practices at Moffitt Cancer Hospital in Tampa, Florida.
What medical group is Dr. Kendra Lynn Sweet part of?
Dr. Sweet is linked to Moffitt Cancer Center.
Does Dr. Kendra Lynn Sweet accept Medicare?
Yes. CMS data shows Dr. Sweet billed Medicare for 44 services in 2024, and Dr. Sweet accepts Medicare assignment.
What is Dr. Kendra Lynn Sweet's MIPS score?
Dr. Sweet's MIPS final score for performance year 2024 is 88 out of 100, reported as part of a group.
How many Medicare patients does Dr. Kendra Lynn Sweet see?
CMS counts 28 Medicare patients who saw Dr. Sweet in 2024, with an average age of 70.
Is Dr. Kendra Lynn Sweet board certified?
Yes. Dr. Sweet is board certified in hematology by the American Board of Internal Medicine.
Show 8 more questionsShow fewer questions
What services does Dr. Kendra Lynn Sweet bill to Medicare?
In 2024, Dr. Sweet's most billed Medicare services were office visit, established patient (99214).
Where did Dr. Kendra Lynn Sweet go to medical school?
Dr. Sweet graduated from VCU School of Medicine in 2007.
What drugs does Dr. Kendra Lynn Sweet prescribe most?
In 2024 Medicare Part D data, Dr. Sweet's most prescribed drugs by claims were Bosulif, Imatinib Mesylate and Ondansetron HCl.
Has Dr. Kendra Lynn Sweet received payments from drug or device companies?
CMS Open Payments shows $231,905 in general payments to Dr. Sweet from 20 companies from 2016 to 2025. The largest total came from Novartis Pharmaceuticals Corporation.
How long has Dr. Kendra Lynn Sweet been practicing?
Dr. Sweet graduated from medical school in 2007, 19 years ago.
Does Dr. Kendra Lynn Sweet do research?
Dmand AI links 93 publications to Dr. Sweet, published from 2012 to 2025. Dr. Sweet has worked on 9 clinical trials.
Who does Dr. Kendra Lynn Sweet publish with?
Dr. Sweet's most frequent co-authors are Jeffrey E. Lancet, MD (52 shared papers), Rami Salah-Eddin Komrokji, MD (49 shared papers) and David A. Sallman, MD (44 shared papers).
What insurance does Dr. Kendra Lynn Sweet accept?
Dr. Sweet is in network with 9 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.
Selling to hematology and oncology practices?
See hematologists and oncologists in Florida by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card